scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111 - scPharmaceuticals ( NASDAQ:SCPH )
BURLINGTON, Mass., Aug. 14, 2025 ( GLOBE NEWSWIRE ) -- scPharmaceuticals Inc.
scPharmaceuticals Receives Notice of Allowances of Multiple US Patent Applications Covering SCP-111
BURLINGTON, Mass., Aug. 14, 2025 ( GLOBE NEWSWIRE ) -- scPharmaceuticals Inc. ( Nasdaq: SCPH ) ( the "Company" ) , a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, announced today that it has received five Notices of Allowance from ...
scPharmaceuticals, Inc. ( SCPH ) Reports Q2 Loss, Lags Revenue Estimates
scPharmaceuticals (SCPH) delivered earnings and revenue surprises of -13.33% and -2.19%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
SCPH Revenue Up 99%
scPharmaceuticals ( NASDAQ:SCPH ) , a commercial-stage pharmaceutical company focused on subcutaneous drug delivery for heart failure and chronic kidney disease patients, delivered its second quarter 2025 earnings results on August 7, 2025.
Cytek Biosciences, Inc. ( CTKB ) Beats Q2 Earnings Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of +150.00% and -3.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
scPharmaceuticals ( SCPH ) Soars 8.8%: Is Further Upside Left in the Stock?
scPharmaceuticals (SCPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
ScPharmaceuticals, Inc. ( SCPH ) Reports Q1 Loss, Misses Revenue Estimates
scPharmaceuticals (SCPH) delivered earnings and revenue surprises of -25.93% and 3.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Insmed ( INSM ) Reports Q1 Loss, Tops Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of -4.41% and 0.18%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
ScPharmaceuticals, Inc. ( SCPH ) Reports Q4 Loss, Tops Revenue Estimates
scPharmaceuticals (SCPH) delivered earnings and revenue surprises of 12.50% and 0.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Lineage Cell ( LCTX ) Reports Q4 Loss, Tops Revenue Estimates
Lineage Cell (LCTX) delivered earnings and revenue surprises of 75% and 160.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease - scPharmaceuticals ( NASDAQ:SCPH )
FDA approves scPharmaceuticals' supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome FUROSCIX is expected to be available for chronic kidney disease patients in April 2025
Will Regenxbio ( RGNX ) Report Negative Earnings Next Week? What You Should Know
Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ScPharmaceuticals, Inc. ( SCPH ) Expected to Beat Earnings Estimates: Should You Buy?
ScPharmaceuticals (SCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ImmunityBio ( IBRX ) Reports Q4 Loss, Misses Revenue Estimates
ImmunityBio (IBRX) delivered earnings and revenue surprises of 42.31% and 13.54%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Certara, Inc. ( CERT ) Surpasses Q4 Earnings and Revenue Estimates
Certara (CERT) delivered earnings and revenue surprises of 15.38% and 0.68%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Vertex Pharmaceuticals ( VRTX ) Misses Q4 Earnings Estimates
Vertex (VRTX) delivered earnings and revenue surprises of -0.25% and 5.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
ScPharmaceuticals, Inc. ( SCPH ) Reports Q3 Loss, Lags Revenue Estimates
scPharmaceuticals (SCPH) delivered earnings and revenue surprises of -23.33% and 7.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Prothena ( PRTA ) Reports Q3 Loss, Misses Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of 6.78% and 53.81%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Monte Rosa Therapeutics ( GLUE ) Reports Q3 Loss, Tops Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of 35.56% and 103.13%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
TScan Therapeutics ( TCRX ) Soars 7.6%: Is Further Upside Left in the Stock?
TScan Therapeutics (TCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
BioMarin Pharmaceutical ( BMRN ) Tops Q3 Earnings and Revenue Estimates
BioMarin (BMRN) delivered earnings and revenue surprises of 16.67% and 5.49%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
scPharmaceuticals to Host Key Opinion Leader ( KOL ) Webinar on October 22, 2024
Webinar to focus on a nephrologist's perspective on the use of FUROSCIX for fluid overload in heart failure and potential use in chronic kidney disease Webinar to focus on a nephrologist's perspective on the use of FUROSCIX for fluid overload in heart failure and potential use in chronic kidney ...
Liquidia Technologies ( LQDA ) Surges 11.2%: Is This an Indication of Further Gains?
Liquidia Technologies (LQDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Does scPharmaceuticals ( SCPH ) Have the Potential to Rally 291.9% as Wall Street Analysts Expect?
The mean of analysts' price targets for scPharmaceuticals (SCPH) points to a 291.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ScPharmaceuticals, Inc. ( SCPH ) Reports Q2 Loss, Tops Revenue Estimates
scPharmaceuticals (SCPH) delivered earnings and revenue surprises of 0% and 0.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Biorestorative Therapies, Inc. ( BRTX ) Reports Q2 Loss, Tops Revenue Estimates
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of 10.71% and 196.67%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
scPharmaceuticals Announces Pricing of $50.0 Million Public Offering
BURLINGTON, Mass., Aug. 12, 2024 ( GLOBE NEWSWIRE ) -- scPharmaceuticals Inc. ( Nasdaq: SCPH ) , a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, ...
Heart Failure-Focused scPharmaceuticals Secures FDA Approval For Expanded Use Of Furoscix, Receives Funding To Expand Commercialization - scPharmaceuticals ( NASDAQ:SCPH )
Monday, the FDA approved scPharmaceuticals Inc.'s SCPH Supplemental New Drug Application, seeking to expand the Furoscix indication for heart failure patients. At approval, Furoscix was only indicated for congestion due to fluid overload in adult patients with New York Heart Association ( NYHA ) ...
scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors - scPharmaceuticals ( NASDAQ:SCPH )
scPharmaceuticals received $75 million through a combination of debt and royalty financings at close, with access to an additional $50 million The term loan refinances existing debt principal. lowers coupon, extends interest-only period for four additional years, and lowers minimum cash ...
scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors
scPharmaceuticals received $75 million through a combination of debt and royalty financings at close, with access to an additional $50 million ...
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure - scPharmaceuticals ( NASDAQ:SCPH )
FUROSCIX is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure, regardless of New York Heart Association ( NYHA ) functional class Indication expansion allows for the use of FUROSCIX in NYHA Class IV chronic heart failure patients
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX Indication in Heart Failure
FUROSCIX is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure, regardless of New York Heart Association ( NYHA ) functional class ...
scPharmaceuticals Announces Positive Topline Study Results for SCP-111 ( Furosemide 80 mg/1 mL ) Autoinjector
SCP-111 Autoinjector achieved primary pharmacokinetic and secondary pharmacodynamic endpoints ...
scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
BURLINGTON, Mass., Aug. 12, 2024 ( GLOBE NEWSWIRE ) -- scPharmaceuticals Inc. ( Nasdaq: SCPH ) ( the "Company" ) , a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce ...
Kiniksa Pharmaceuticals, Ltd. ( KNSA ) Reports Q2 Loss, Tops Revenue Estimates
Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of 33.33% and 23.68%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ScPharmaceuticals, Inc. ( SCPH ) Reports Q1 Loss, Lags Revenue Estimates
scPharmaceuticals (SCPH) delivered earnings and revenue surprises of 20% and 6.17%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
MaxCyte, Inc. ( MXCT ) Reports Q1 Loss, Tops Revenue Estimates
MaxCyte (MXCT) delivered earnings and revenue surprises of 35.71% and 46.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
SpringWorks Therapeutics ( SWTX ) Reports Q1 Loss, Tops Revenue Estimates
SpringWorks Therapeutics (SWTX) delivered earnings and revenue surprises of -0.85% and 76.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Global Tissue Banking Market to Exhibit Growth at a Considerable CAGR of ~6% by 2030, Assesses DelveInsight
The tissue banking market is experiencing a surge in demand due to several factors: the growing prevalence and occurrence of chronic illnesses, the expanding elderly population susceptible to such ailments, and the potential breakthroughs in treating cancers, blood disorders, immune conditions, ...
Drug-Eluting Balloons Global Market is Expected to Expand at a Healthy Growth Rate of ~8% by 2028, Predicts DelveInsight
Drug-Eluting Balloons Global Market is Expected to Expand at a Healthy Growth Rate of ~8% by 2028, Predicts ... PR ...
Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts DelveInsight
The dynamics of the heart failure market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, and incremental healthcare spending across the world.
scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 )
BURLINGTON, Mass., Oct. 05, 2023 ( GLOBE NEWSWIRE ) -- scPharmaceuticals Inc. ( Nasdaq: SCPH ) ( "scPharmaceuticals" or the "Company" ) , a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce ...
ScPharmaceuticals, Inc. ( SCPH ) Reports Q2 Loss, Tops Revenue Estimates
scPharmaceuticals, Inc. (SCPH) delivered earnings and revenue surprises of 2.70% and 5.68%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
scPharmaceuticals, Inc. ( SCPH ) Loses -21.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for scPharmaceuticals, Inc. (SCPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...
Short Interest Sector Focus: Healthcare Sector - Novavax ( NASDAQ:NVAX )
As of the close of business on Wednesday, 6/28, we captured the Top 10 Highest Short Interest % stocks within the Healthcare sector. The average short interest for stocks within the Healthcare sector stands at 3.48%.
Short Interest Sector Focus: Healthcare Sector - Novavax ( NASDAQ:NVAX )
As of the close of business on Tuesday, 6/27, we captured the Top 10 Highest Short Interest % stocks within the Healthcare sector. The average short interest for stocks within the Healthcare sector stands at 3.51%. Therefore, the below stocks are showing a more pessimistic outlook than their ...
scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes
BURLINGTON, Mass., June 23, 2023 ( GLOBE NEWSWIRE ) -- scPharmaceuticals Inc. ( Nasdaq: SCPH ) , a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, ...
scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes - scPharmaceuticals ( NASDAQ:SCPH )
BURLINGTON, Mass., June 23, 2023 ( GLOBE NEWSWIRE ) -- scPharmaceuticals Inc.
scPharmaceuticals to Present at the Jefferies Healthcare Conference
BURLINGTON, Mass., May 31, 2023 ( GLOBE NEWSWIRE ) -- scPharmaceuticals Inc. ( Nasdaq: SCPH ) , a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, ...
ScPharmaceuticals, Inc. ( SCPH ) Reports Q1 Loss, Misses Revenue Estimates
scPharmaceuticals, Inc. (SCPH) delivered earnings and revenue surprises of 16.67% and 20.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
